NYMOX
Manufacturing · Bahamas · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Bay & Deveaux Sts, Nassau, New Providenc...Phone Number
(800) 936-9669Website
www.nymox.comRevenue
<$5 MillionStock Symbol
NYMXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About NYMOX
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease, as well as researches and develops drug treatments for Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, the Bahamas.Explore more
NYMOX Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NYMOX your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once NYMOX has new funding data
Product Launch: Get notified when NYMOX launches new products
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on NYMOX recently announced quarterly report
NYMOX, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at NYMOX
Check if NYMOX has recently received funding, and reach out quickly before it becomes old news!
Click to see if NYMOX had a recent Job posting/layoffs
Check out if NYMOX is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined NYMOX as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
NYMOX is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
NYMOX is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about NYMOX.
NYMOX financials insights
Gather financial insights about NYMOX, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Share Placement
$6.4M
NYMOX Tech Stack
A closer look at the technologies used by NYMOX
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Funding
New Hire
Executive Move
Mark Staples has joined the company as Vice President, Chemistry, Manufacturing & Controls. Previously, Staples served as Founder & CMC Consultant at Cusp Pharmatech Consulting LLC.
Executive Moves, New Hire
Facilities Relocation / Expansion
NYMOX has announced plans to move its corporate headquarters from the Bahamas to Switzerland.
Facilities Relocation/Expansion
Funding
Funding
NYMOX News & Media
NYMOX Announces Trading Resumed and New Listing on OTCQB Market
IRVINE Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that the Company's stock has resumed trading under the symbol NYMXF on the Over the Counter QB (OTCQB®) Venture Market. This is a higher level tier from the Company's prior listing. With the new OTCQB listing, Nymox’s stock is now eligible for proprietary broker-dealer quotations.Nymox Announces Filing of Annual Report
IRVINE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) is pleased to report that it filed its Annual Report with the Security and Exchange Commission (SEC) on August 29, 2024.Nymox Annual Report
IRVINE, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that its Annual Report is and has been in progress since late February, soon after Nymox received some of its corporate documents withheld by the terminated officers and directors. Unfortunately, this has caused delays beyond the Company’s control in its completion. The Company believes that the audit will be completed soon, and it will issue its annual reportNymox Required to Resubmit Application to DKMA
IRVINE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that its MAA submission to the Danish Medicines Agency (DKMA) has run out of time and in order to continue will be required to extend the MAA application to DKMA by re-submission with a new fee required. As it currently stands the application “does not meet the conditions of the Medicines Act for issuing a marketing authorization.” Although
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding NYMOX
Sign Up For FreeTo access detailed company insights
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasi... Read More
